Hyperhidrosis Treatment Market Size, Share, Growth Analysis, By Treatment(Botulinum toxic A, lontophoresis, surgical treatment, tropical treatment), By Type(Primary focal, secondary generalized), By End User(Hospitals, ambulatory, surgical centers, others), By Region - Industry Forecast 2025-2032

Hyperhidrosis Treatment Market size was valued at USD 605.1 Million in 2023 and is poised to grow from USD 635.96 Million in 2024 to USD 999.19 Million by 2032, growing at a CAGR of 5.1% during the forecast period (2025-2032).

For treating hyperhidrosis, antiperspirants and topical treatments are the first line of defense. Hyperhidrosis, however, still has no known permanent treatment. There has been a lot of activity in recent years regarding technological and product developments. Companies have been encouraged to invest in this industry by the patients' preference for novel approaches and the growing understanding of the treatment choices.

The prevalence of secondary hyperhidrosis disorders is on the rise, and market participants are increasing their spending in R&D, which are the main drivers of market growth for hyperhidrosis treatments. According to a study by Jared Brackenrich that was published in the National Library of Medicine in October 2021, this disorder is thought to be relatively common in the United States, with an estimated 3% prevalence. Hyperhidrosis can impede social, psychological, emotional, and vocational functioning. Therefore, it is projected that the growing prevalence of hyperhidrosis will increase demand for therapy and consequently accelerate market expansion.

Another aspect that may have an impact on market expansion is the promising therapy pipeline for hyperhidrosis, as well as the presence of advantageous reimbursement policies, rising rates of anxiety and depression, and increased public awareness of hyperhidrosis. As an example, Brickell Biotech Inc. released encouraging topline findings from the Phase 3 pivotal Cardigan I and Cardigan II studies in October 2021. These studies assessed the effectiveness of 15% sofpironium bromide gel as a once-daily topical formulation in people with primary axillary hyperhidrosis.

US Hyperhidrosis Treatment Market is poised to grow at a sustainable CAGR for the next forecast year.